State Street Corp Raises Stock Position in Twist Bioscience Co. (NASDAQ:TWST)

State Street Corp lifted its position in Twist Bioscience Co. (NASDAQ:TWST) by 19.9% during the third quarter, Holdings Channel reports. The institutional investor owned 3,167,353 shares of the company’s stock after buying an additional 526,028 shares during the quarter. State Street Corp owned about 0.05% of Twist Bioscience worth $143,101,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Signaturefd LLC grew its position in shares of Twist Bioscience by 63.0% in the 3rd quarter. Signaturefd LLC now owns 792 shares of the company’s stock worth $36,000 after buying an additional 306 shares during the last quarter. EdgeRock Capital LLC purchased a new stake in Twist Bioscience during the 2nd quarter worth approximately $43,000. Blue Trust Inc. grew its position in Twist Bioscience by 2,912.8% during the 2nd quarter. Blue Trust Inc. now owns 1,175 shares of the company’s stock worth $58,000 after purchasing an additional 1,136 shares during the last quarter. DekaBank Deutsche Girozentrale purchased a new stake in Twist Bioscience during the 2nd quarter worth approximately $61,000. Finally, Mirae Asset Global Investments Co. Ltd. grew its position in Twist Bioscience by 21.9% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,119 shares of the company’s stock worth $98,000 after purchasing an additional 381 shares during the last quarter.

Twist Bioscience Trading Up 0.2 %

Shares of NASDAQ TWST opened at $47.50 on Friday. The company has a 50 day simple moving average of $44.94 and a two-hundred day simple moving average of $46.63. Twist Bioscience Co. has a 12 month low of $27.41 and a 12 month high of $60.90. The stock has a market cap of $2.82 billion, a price-to-earnings ratio of -13.19 and a beta of 1.82.

Insider Activity at Twist Bioscience

In related news, CFO Adam Laponis sold 856 shares of the business’s stock in a transaction on Wednesday, October 9th. The shares were sold at an average price of $41.81, for a total value of $35,789.36. Following the completion of the transaction, the chief financial officer now directly owns 73,397 shares in the company, valued at $3,068,728.57. The trade was a 1.15 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, SVP Paula Green sold 860 shares of the business’s stock in a transaction on Friday, December 6th. The shares were sold at an average price of $52.70, for a total transaction of $45,322.00. Following the completion of the transaction, the senior vice president now owns 133,715 shares of the company’s stock, valued at approximately $7,046,780.50. This represents a 0.64 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 101,787 shares of company stock worth $4,584,508 in the last three months. Company insiders own 3.92% of the company’s stock.

Wall Street Analyst Weigh In

Several analysts have weighed in on TWST shares. Evercore ISI boosted their target price on shares of Twist Bioscience from $52.00 to $56.00 and gave the stock an “outperform” rating in a research report on Tuesday, October 1st. TD Cowen reissued a “buy” rating and set a $58.00 target price on shares of Twist Bioscience in a research report on Tuesday, November 26th. Robert W. Baird boosted their target price on shares of Twist Bioscience from $46.00 to $48.00 and gave the stock an “outperform” rating in a research report on Tuesday, November 19th. Scotiabank boosted their target price on shares of Twist Bioscience from $50.00 to $54.00 and gave the stock a “sector outperform” rating in a research report on Tuesday, November 19th. Finally, Leerink Partners lifted their price objective on shares of Twist Bioscience from $45.00 to $48.00 and gave the company a “market perform” rating in a research note on Thursday, October 17th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and eight have given a buy rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $51.90.

Twist Bioscience Company Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.